Redeye comments on Alzinova’s announcement of having submitted an IND application and a Fast Track Designation request to the FDA for ALZ-101. We view this as a significant step toward initiating the planned phase II trial, marking clear progress in the regulatory process. With a CRO already in place, the focus now shifts to securing the necessary financing, preferably through a licensing agreement with a strategic partner.
LÄS MER
